Biggest News Aggregation in the World
๐Ÿ“ฐ Critically Ill News

Page 2 - Critically Ill News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Critically Ill. Real-time updates on events, politics, business and more.

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults

XACDURO is a new FDA-approved treatment used to fight against HABP/VABP infections caused by isolates of Acinetobacter baumannii-calcoaceticus complex, which can include those resistant to...
United States Margaret Koziel Tragiannidisa Acinetobacter Pavel Raifeld Innoviva Inc Securities Exchange

XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Ho

XACDURO is a new FDA-approved treatment used to fight against HABP/VABP infections caused by isolates of Acinetobacter baumannii-calcoaceticus complex, which can include those resistant to carbapenems (CRAB).In the U.S., it is estimated there are more than 40,000 cases of Acinetobacter each year and approximately 40...
United States Pavel Raifeld Margaret Koziel Tragiannidisa Acinetobacter Yuk National Prevalence Innoviva Specialty Therapeutics Inc

InflaRx: EMA Reviews MAA For Vilobelimab For Critically Ill COVID-19 Patients; Stock Up In Premarket

InflaRx N.V. (IFRX), a biotechnology company pioneering anti-inflammatory therapeutics targeting the complement system, Wednesday said the European Medicines Agency or EMA has validated its Marketing Authorization Application or MAA for Vilobelimab to treat Critically Ill COVID-19 Patients.
United States European Medicines Agency European Committee For Medicinal Products Human More Such Health News Drug Administration European Union

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News โ†’

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science